Meeting Banner
Abstract #4031

Sildenafil improves vascular and metabolic function in patients with Alzheimer’s Disease

Hanzhang Lu1, Min Sheng2, Peiying Liu1, Harshan Ravi1, Shin-Lei Peng1, Ramon Diaz-Arrastia3, Michael D. Devous Sr.4, and Kyle B. Womack5

1Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, United States, 2Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX, United States, 3Center for Neuroscience and Regenerative Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, United States, 4Avid Radiopharmaceuticals, Inc., Philadelphia, PA, United States, 5Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, United States

Alzheimer’s disease (AD) is the leading cause of degenerative dementia in the aging population. Patients with AD have alterations in cerebral hemodynamic function. Therefore, improved cerebrovascular function may be an attractive goal for pharmaceutical intervention in AD. Our study applied several novel non-invasive MRI techniques to investigate the alterations of CBF, cerebral metabolic rate of oxygen (CMRO2) and cerebrovascular reactivity (CVR) after a single dose of sildenafil administration in order to assess its physiological effects in AD patients. Our data suggest that a single dose of sildenafil improves cerebral hemodynamic function and increases cerebral oxygen metabolism in patients with AD.

This abstract and the presentation materials are available to members only; a login is required.

Join Here